| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institute of Clinical Medicine (R.J., K.W.), University of Tromsø, 9037 Tromsø, Norway; Departments of Internal Medicine (H.S., A.N.) and Clinical Chemistry (J.S.), University Hospital of North Norway, 9038 Tromsø, Norway; and Department of Nephrology (T.G.J.), National Hospital, 0027 Oslo, Norway
Address all correspondence and requests for reprints to: Rolf Jorde, Medical Department B, University Hospital of North Norway, 9038 Tromsø, Norway. E-mail: rolf.jorde{at}unn.no.
Objective: Our objective was to examine the relation between neuropsychological function and subclinical hypothyroidism (SHT), defined as serum TSH of 3.5–10.0 mIU/liter and normal serum free T4 and free T3 levels, and to study the effect of T4 supplementation.
Subjects: A total of 89 subjects (45 males) with SHT and 154 control subjects (72 males) were recruited from a general health survey (the fifth Tromsø study). Sixty-nine of those with SHT were included in a placebo-controlled, double-blind intervention study with T4 medication for 1 yr.
Main Outcome Measures: We used fourteen tests of cognitive function, Beck Depression Inventory, General Health Questionnaire, and a questionnaire on hypothyroid symptoms.
Results: The mean ± SD serum TSH in the SHT and control group were 5.57 ± 1.68 and 1.79 ± 0.69 mIU/liter, respectively. There were no significant differences in cognitive function and hypothyroid symptoms between the two groups, but those with SHT scored significantly better than the controls on the GHQ-30. At the end of the intervention study, serum TSH in the T4 group (n = 36) and the placebo group (n = 33) were 1.52 ± 1.51 and 5.42 ± 1.96 mIU/liter, respectively. T4 substitution had no effect on any of the parameters measured.
Conclusion: In subjects with SHT where the serum TSH level is in the 3.5–10.0 mIU/liter range, there is no neuropsychological dysfunction, and compared with healthy controls, there is no difference in symptoms related to hypothyroidism.
This article has been cited by other articles:
 |
|
 |
|
  B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Meyerovitch, P. Rotman-Pikielny, M. Sherf, E. Battat, Y. Levy, and M. I. Surks Serum Thyrotropin Measurements in the Community: Five-Year Follow-up in a Large Network of Primary Care Physicians Arch Intern Med, July 23, 2007; 167(14): 1533 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Samuels, K. G. Schuff, N. E. Carlson, P. Carello, and J. S. Janowsky Health Status, Mood, and Cognition in Experimentally Induced Subclinical Hypothyroidism J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2545 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Razvi, L. Ingoe, G. Keeka, C. Oates, C. McMillan, and J. U. Weaver The Beneficial Effect of L-Thyroxine on Cardiovascular Risk Factors, Endothelial Function, and Quality of Life in Subclinical Hypothyroidism: Randomized, Crossover Trial J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1715 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Roberts, H. Pattison, A. Roalfe, J. Franklyn, S. Wilson, F.D. R. Hobbs, and J. V. Parle Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med, October 17, 2006; 145(8): 573 - 581. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
